Patents Assigned to Boehringer Ingelheim International GmbH
  • Publication number: 20220193347
    Abstract: An administration device for in particular intravitreal administration of a fluid, the administration device having a preferably pre-filled syringe and an actuation mechanism for actuating the syringe. The administration device preferably includes a priming device, in particular in addition to the actuation mechanism. It is preferably prevented that the priming device be advanced beyond a defined end position. The syringe can preferably be moved within a housing of the administration device and/or positioned completely inside the housing.
    Type: Application
    Filed: April 16, 2020
    Publication date: June 23, 2022
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Axel ROTH, Viola K. HOLMAN, Hans J√łergen JENSEN
  • Patent number: 11358967
    Abstract: The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: June 14, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Delphine Collin, Johanna Csengery, Robert Owen Hughes, Michael Robert Turner, Lifen Wu
  • Publication number: 20220177479
    Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Application
    Filed: November 10, 2021
    Publication date: June 9, 2022
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach
  • Patent number: 11339161
    Abstract: The present invention relates to triazolo pyridines of formula (II) and their use as modulators of #-secretase. In particular, the present invention relates to compounds which interfere with #-secretase and/or its substrate and therefore modulate the formation of A? peptides. Accordingly these compounds can be used for the treatment of A?-related pathologies, e.g. Alzheimer's disease.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 24, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Niklas Heine, Christian Eickmeier, Kai Gerlach, Ulrike Gross
  • Publication number: 20220153857
    Abstract: The present invention related to new humanized antanogistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 19, 2022
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias Litzenburger, Sanjaya Singh
  • Patent number: 11332541
    Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: May 17, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Priyanka Gupta, Justin Scheer, Vladimir H. Voynov, Pankaj Gupta
  • Patent number: 11331322
    Abstract: A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. A method of preventing and/or treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol or a salt thereof to the subject is also provided.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: May 17, 2022
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Kenji Oki, Takashi Nagano, Nagayoshi Asano, Koushi Fujisawa
  • Patent number: 11324724
    Abstract: The present invention relates to novel N-(2,2-difluoroethyl)-N-[(Pyrimidinylamino)propanyl]-arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: May 10, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Niklas Heine, Uta Friederike Lessel, Stefan Scheuerer
  • Publication number: 20220135261
    Abstract: A method for producing a cartridge is proposed, where a fluid is filled into an opening of a container and a closure part is inserted into the container, thereby moving a movable piston arranged within the container.
    Type: Application
    Filed: December 13, 2019
    Publication date: May 5, 2022
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Joachim EICHER, Gilbert WUTTKE, Herbert GRAESSL
  • Patent number: 11319318
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R9, X1 and X2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. cancer, pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: May 3, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Laetitia Martin, Steffen Steurer, Xiao-Ling Cockcroft
  • Patent number: 11319310
    Abstract: The present invention relates to compounds of general formula (I) wherein the variables X, R1, n, p and q are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: May 3, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Viktor Vintonyak
  • Patent number: 11312785
    Abstract: The present invention relates to novel antagonizing antibodies for CD73. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 26, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Irmgard Maria Rita Hofmann, Jennifer Ahlberg, Rajkumar Ganesan, Priyanka Gupta, Sven Mostboeck, Simon Plyte, Otmar Schaaf, Chia-Hung Tsai, Melanie Wurm, Markus Zettl, Jark Boettcher, Bruna De Andrade Pereira
  • Patent number: 11304929
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: April 19, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Weinstabl, Georg Dahmann, Matthias Treu, Bernd Wellenzohn, Stephan Karl Zahn
  • Patent number: 11298476
    Abstract: Disclosed is an inhaler and a method for using the inhaler for the inhalation of a formulation from a carrier. The carrier contains the formulation in a receptacle and is set oscillating by an air current. An improved or defined delivery and nebulisation of the preferably powdered formulation is made possible by the fact that the carrier is set oscillating in defined manner, the formulation is dispensed through a cover element having three to five holes and/or the air current flows onto a fin associated with the carrier and flows past at least substantially only one flat side of the carrier.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: April 12, 2022
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Andree Jung, Stephen Terence Dunne
  • Patent number: 11298295
    Abstract: A system and a method for medication adherence management with which a medicament container is held by a holding apparatus, a detector device wirelessly recognizes an opening and closing activity of the medicament container, and a data processing device or control device reads and processes data of the detector device.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: April 12, 2022
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventor: Holger Bartos
  • Patent number: 11299538
    Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: April 12, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Eric Borges, Robert Rauchenberger, Gabriela Wochnik-Veltrup
  • Patent number: 11291668
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: April 5, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • Patent number: 11267880
    Abstract: The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: March 8, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Leo Thomas, Rachel Rebecca Barrett, Kristin Laura Bovat, Rajkumar Ganesan, Priyanka Gupta, Fei Han, Dongmei Liu, Juergen Prestle, Sanjaya Singh, Sathyadevi Venkataramani, Helen Haixia Wu, Nina Zippel
  • Patent number: 11261184
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R5, A and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: March 1, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Heribert Arnhof, Sebastian Carotta, Marco Hofmann, Marc Kerenyi, Dirk Scharn
  • Publication number: 20220056032
    Abstract: The present invention relates to compounds of formula (I) a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Application
    Filed: December 10, 2019
    Publication date: February 24, 2022
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach